Targeted Therapy in Solid Tumors: Colorectal Cancer

Maen Abdelrahim, Scott Kopetz, David G. Menter

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Although the overall incidence of colorectal cancer is slowly decreasing in some populations older than 50 years, the young-onset incidence is increasing. Each patient with colorectal cancer exhibits unique disease characteristics that are driven by discrete genetic/epigenetic aberrations requiring effective identification prior to treatment. Improvements in sequencing technology have helped establish molecular subsets of disease that serve as predictors of prognosis and selection of the appropriate targeted therapy. Advances in the targeted therapy of colorectal cancer in recent years along with molecular subset identification have significantly improved the therapeutic outcomes. Surface receptors that can be targeted using humanized antibodies continue to emerge, and small molecules to target their downstream signaling cascades are being developed. Molecules that target more than one pathway within complex signaling networks have been shown to have significant effects on advanced metastatic disease. The overall prognosis of patients with colorectal cancer continues to improve.

Original languageEnglish (US)
Title of host publicationTargeted Therapy in Translational Cancer Research
PublisherWiley
Pages193-204
Number of pages12
ISBN (Electronic)9781118468678
ISBN (Print)9781118468579
DOIs
StatePublished - Oct 30 2015

Keywords

  • Aflibercept
  • Bevacizumab
  • BRAF
  • Cetuximab
  • EGFR
  • KRAS
  • NRAS
  • Panitumumab
  • Regorafenib
  • VEGF

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Targeted Therapy in Solid Tumors: Colorectal Cancer'. Together they form a unique fingerprint.

Cite this